Desensitization: achieving immune detente.

Area of Science:

• Immunology
• Transplantation Medicine
• Nephrology

Background:

• Donor-specific antibodies (human leukocyte antigen [HLA] and ABO antigens) historically contraindicated organ transplantation.
• Desensitization protocols have emerged as a viable strategy to overcome antibody barriers.
• These protocols aim to reduce antibody levels, enabling transplantation in previously ineligible patients.

Purpose of the Study:

• To evaluate the efficacy and outcomes of desensitization protocols in organ transplantation.
• To compare different desensitization strategies, including IVIg and plasmapheresis.
• To assess the long-term risks and management of antibody-mediated rejection (AMR) post-transplantation.

Main Methods:

• Utilized high-dose intravenous immunoglobulin (IVIg) or plasmapheresis with low-dose IVIg as primary desensitization strategies.
• Administered standard immunosuppressive agents alongside adjunctive therapies like cell-depleting antibodies.
• Monitored antibody titers and graft function post-transplantation.

Main Results:

• Successful transplantation achieved in ABO-incompatible (ABOi) and HLA-positive crossmatch renal transplants.
• Graft and patient survival rates comparable to non-sensitized recipients.
• Desensitized patients exhibit a higher incidence of antibody-mediated rejection (AMR).

Conclusions:

• Desensitization protocols significantly expand the donor pool for organ transplantation.
• Persistent antibodies post-transplantation increase AMR risk, necessitating continuous monitoring.
• Desensitization research offers insights into immune dysfunction and regulatory processes.